Flickdox O 100 Tablet contains Cefpodoxime Proxetil 100 mg and Ofloxacin 100 mg, a broad-spectrum antibiotic combination formulated for the treatment of various susceptible bacterial infections. The combination provides dual antibacterial action against a wide range of gram-positive and gram-negative microorganisms, helping control infection and support recovery. It is prescribed under medical supervision for conditions where combination antibiotic therapy is considered appropriate based on the clinical presentation and bacterial susceptibility.
Cefpodoxime Proxetil is a third-generation cephalosporin antibiotic that works by inhibiting bacterial cell wall synthesis, leading to the destruction of susceptible bacteria. Ofloxacin is a fluoroquinolone antibiotic that interferes with bacterial DNA replication and repair processes, preventing bacterial growth and multiplication. Together, these ingredients offer complementary antibacterial activity that helps enhance infection control and therapeutic effectiveness.
The tablet is commonly prescribed for respiratory tract infections, urinary tract infections, gastrointestinal infections, ENT infections, skin and soft tissue infections, and other bacterial conditions as advised by a healthcare professional. Appropriate use helps reduce infection-related symptoms, prevent disease progression, and support complete recovery. The medicine should be taken exactly as prescribed, and the full course of therapy should be completed to help reduce the risk of bacterial resistance.
With the continued prevalence of bacterial infections and the growing demand for effective anti-infective therapies, Flickdox O 100 Tablet maintains strong relevance in the antibiotic segment. Its broad-spectrum coverage, physician acceptance, and established clinical utility contribute to sustained market demand. The product offers valuable business opportunities and long-term growth potential for retailers and distributors operating within the anti-infective pharmaceutical sector.